BYSI
BeyondspringยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
BYSI Profile
Beyondspring Inc.
A clinical stage global biopharmaceutical company that focused on developing innovative cancer therapies
Pharmaceutical
11/21/2014
03/09/2017
NASDAQ Stock Exchange
40
12-31
Common stock
100 Campus Drive, West Side, 4th Floor, Suite 410, Florham Park, New Jersey 07932
Innovative development of cancer treatments
Beyondspring Inc. was incorporated in the Cayman Islands on November 21, 2014. The company is a global clinical-stage biopharmaceutical company focused on novel cancer therapies, including the development of advanced tumor immune drugs. At Wanchun Medicine, its mission is to use their academic and business capabilities in cancer treatment to change the status quo of cancer treatment in a unique way. The company was founded in 2013 and is headquartered in the United States. Their main project, punabulin, is derived from natural compounds and has therapeutic potential for a variety of cancers due to its various biochemical activities. They adopt a novel and highly scalable business model, integrate the superior resources of the United States and China, and realize the approval and development of drugs with high efficiency and low cost.
